PUBLIC CONTRACT · 2021
2021008522– Aquisição de Vedolizumab 300 mg Pó conc sol inj Fr IV
- Contract value
- €8,059.38
- Signed on
- 1 October 2021
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 7884804PUBLISHED SUBJECT
2021008522– Aquisição de Vedolizumab 300 mg Pó conc sol inj Fr IV
WHO CONTRACTED
Parties involved
- Place of performance
- Portugal
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- Takeda Farmacêuticos Portugal, Lda · Tax ID 502801204
HOW MUCH AND WHEN
Values and timeline
- Contract price
- €8,059.38
- Procedure base price
- €8,059.38
- Total effective price
- Not reported on Portal BASE
- Publication date
- 1 October 2021
- Award date
- 20 September 2021
- Signing date
- 1 October 2021
- Performance period
- 5 days
The contract price is the value agreed in the contract, not the amount paid.
HOW IT WAS CONTRACTED
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Multifator
- CPV code
- 33652000-5 - Antineoplásicos e imunomoduladores
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea iii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos ( DL 111-B/2017 )
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5453307
KEEP EXPLORING
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.